logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
Showing 1 - 7 of 7 Items
Showing 1 - 7 of 7 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (7)
  • CSV
  • BibTeX
  • EndNote
  • All Results (7)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Ali MH,  et al.
2025-07-16 • Lancet Respiratory Medicine
2025-07-16 • Lancet Respiratory Medicine
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Protocol
Journal Article
|
Research
Journal Article
|
Letter
Journal Article
|
Commentary

Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A,  et al.
2025-01-29 • New England Journal of Medicine
2025-01-29 • New England Journal of Medicine

BACKGROUND

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...

Standards for clinical trials for treating TB

du Cros PAK, Greig J, Cross GB, Cousins C, Berry C,  et al.
2023-12-01 • International Journal of Tuberculosis and Lung Disease
2023-12-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The value, speed of completion and robustness of the evidence generated by TB treatment trials could be improved by implementing standards for best practice.

METH...

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial

Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E,  et al.
2021-09-25 • Trials
2021-09-25 • Trials
BACKGROUND
Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. W...

Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults

Furin J, Alirol E, Allen E, Fielding K, Merle CS,  et al.
2016-03-01 • International Journal of Tuberculosis and Lung Disease
2016-03-01 • International Journal of Tuberculosis and Lung Disease
Drug-resistant tuberculosis (DR-TB) is a growing public health problem, and for the first time in decades, new drugs for the treatment of this disease have been developed. These new dru...

Efficacy, Safety and Tolerability of Linezolid for the Treatment of XDR-TB: a Study in China

Berry C, Yates TA, Seddon JA, Phillips PPJ, du Cros PAK
2016-05-01 • European Respiratory Journal
2016-05-01 • European Respiratory Journal

Principles for designing future regimens for multidrug-resistant tuberculosis

Brigden G, Nyang'wa BT, du Cros PAK, Varaine FFV, Hughes J,  et al.
2014-01-01 • Bulletin of the World Health Organization
2014-01-01 • Bulletin of the World Health Organization
Fewer than 20% of patients with multidrug-resistant (MDR) tuberculosis are receiving treatment and there is an urgent need to scale up treatment programmes. One of the biggest barriers t...